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to peripheral IL-1b maturation
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Abstract
Background: Caspase-1 is a cysteine protease responsible for the processing and secretion of IL-1b and IL-18,
which are closely related to the induction of inflammation. However, limited evidence addresses the participation
of caspase-1 in inflammatory pain. Here, we investigated the role of caspase-1 in inflammatory hypernociception
(a decrease in the nociceptive threshold) using caspase-1 deficient mice (casp1-/-).
Results: Mechanical inflammatory hypernociception was evaluated using an electronic version of the von Frey test.
The production of cytokines, PGE2 and neutrophil migration were evaluated by ELISA, radioimmunoassay and
myeloperoxidase activity, respectively. The interleukin (IL)-1b and cyclooxygenase (COX)-2 protein expression were
evaluated by western blotting. The mechanical hypernociception induced by intraplantar injection of carrageenin,
tumour necrosis factor (TNF)a and CXCL1/KC was reduced in casp1-/- mice compared with WT mice. However, the
hypernociception induced by IL-1b and PGE2 did not differ in WT and casp1-/- mice. Carrageenin-induced TNF-a
and CXCL1/KC production and neutrophil recruitment in the paws of WT mice were not different from casp1-/-
mice, while the maturation of IL-1b was reduced in casp1-/- mice. Furthermore, carrageenin induced an increase in
the expression of COX-2 and PGE2 production in the paw of WT mice, but was reduced in casp1-/- mice.
Conclusion: These results suggest that caspase-1 plays a critical role in the cascade of events involved in the
genesis of inflammatory hypernociception by promoting IL-1b maturation. Because caspase-1 is involved in the
induction of COX-2 expression and PGE2 production, our data support the assertion that caspase-1 is a key target
to control inflammatory pain.
Background
Inflammatory hypernociception results mainly from the
sensitisation of primary afferent neurons and is detected
as a decrease of the nociceptive threshold in animal mod-
els [1]. It is induced by inflammatory mediators, such as
prostaglandins and sympathetic amines, that directly sen-
sitise peripheral nociceptive neurons [2-4]. The release of
these direct-acting hyperalgesic mediators is generally
preceded by a cascade of cytokines [5]. Recently, we
demonstrated that inflammatory hypernociception in
mice is mediated by a concomitant release of tumour
necrosis factor alpha (TNFa) and keratinocyte-derived
chemokine (CXCL1/KC). Both mediators stimulate the
subsequent release of interleukin (IL)-1b that in turn
induces prostanoid production [6]. CXCL1/KC also sti-
mulates the sympathetic component of inflammatory
hypernociception [6]. Another important event that
mediates inflammatory hypernociception is neutrophil
migration [7]. It has also been demonstrated that the
hyperalgesic effect of cytokines depends on neutrophil
recruitment that, in the last instance, seems to be impor-
tant for the production of directly-acting hyperalgesic
mediators such as prostaglandin E2 (PGE2) [7].
Caspase-1 (previously known as IL-1 converting
enzyme -ICE) is a member of the caspase family of pro-
teases and is responsible for the processing and secre-
tion of IL-1b and IL-18, two cytokines that are critical
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for inflammation [8,9]. For instance, caspase-1-deficient
mice (casp1-/-) have a defect in the maturation of pro-
IL-1b and pro-IL-18 and are resistant to LPS-induced
endotoxic shock [10]. Furthermore, the treatment of
mice with a selective inhibitor of caspase-1 had reduced
collagen-induced arthritis [11]. In this context, caspase-1
was considered an important target to control inflam-
matory diseases.
Although the action of caspase-1 in the maturation of
IL-1b and IL-18 is an important step in the cascade of
inflammatory events, there have been limited studies that
investigate its role in the genesis of inflammatory pain
[12,13]. For instance, a selective inhibitor of caspase-1 was
found to inhibit yeast-induced hypernociception in rats
[12]. Nonetheless, more conclusive evidence about the
participation and the role of caspase-1 in inflammatory
hypernociception is required. In the present study, we
addressed the role of caspase-1 in carrageenin-induced
mechanical inflammatory hypernociception using mice
deficient in this enzyme. We focused mainly in the periph-
eral mechanisms involved in caspase-1 mediation of this
inflammatory symptom. Our results indicate that caspase-
1 plays a crucial role in genesis of inflammatory pain by
promoting IL-1b maturation in the site of inflammation.
Results
Caspase-1-/- mice show reduced mechanical inflammatory
hypernociception
In the first set of experiments we evaluated the mechan-
ical nociceptive threshold of WT and casp1-/- mice.
Mechanical nociceptive thresholds of casp1-/- mice did
not differ from WT littermates (Figure 1A). On the
other hand, carrageenin-induced mechanical hypernoci-
ception was reduced in casp1-/- mice compared with
WT mice. These differences were observed 3 and 5 h
after stimuli injection (Figure 1B). The reduction in
inflammatory hypernociception in casp1-/- mice was not
accompanied by a reduction in carrageenin-induced paw
oedema (WT/Saline 0.01 ± 0.003 mm3; WT/carrageenin
0,075 ± 0,007 mm3 casp1-/-Saline 0,01 ± 0,004 mm3;
casp1-/-/carrageenin 0,06 ± 0,005 mm3).
For a clinical perspective, we evaluated the effect of a
selective inhibitor of caspase-1 (Ac-YVAD-CMK) on
inflammatory hypernociception. It was observed that the
pretreatment of mice with YVAD-CMK (1-9 mg/kg s.c.;
30 min before carrageenin injection), inhibited carragee-
nin-induced mechanical hypernociception in a dose-
dependent manner (Figure 1C).
Neither neutrophil nor pro-nociceptive cytokines (TNFa
and CXCL1/KC) are involved in caspase-1 mediation of
inflammatory hypernociception
Next, it was evaluated whether the reduction of
inflammatory hypernociception in casp1-/- mice was
associated with a reduction in the production of pro-
nociceptive cytokines (TNFa or chemokines CXCL1/
KC) or associated with a reduction in neutrophil
migration. It was observed that the increase in the pro-
duction of TNFa and CXCL1/KC after intraplantar
injection of carrageenin in WT mice was not different
from casp-1-/- mice (Figure 2A and B, respectively).
Carrageenin-induced neutrophil migration was also not
reduced in casp1-/- mice compared with WT mice
(Figure 2C). In agreement with these findings, the
doses of YVAD-CMK that inhibited carrageenin-
induced mechanical hypernociception did not alter
carrageenin-induced neutrophil migration (data not
shown).
Caspase-1 mediates TNFa and CXCL1/KC-induced
mechanical hypernociception but is not induced by IL-1b
or PGE2
Mechanical hypernociception induced by intraplantar
injection of TNFa or CXCL1/KC was reduced in
casp1-/- mice compared with WT mice (Figure 3A). On
the other hand, the mechanical hypernociception induced
by IL-1b or by PGE2 was not different in casp1-/- mice
compared with WT mice (Figure 3A and 3B).
IL-1b maturation in the inflammatory site, but not
maturation of IL-18, accounts for caspase-1 mediation of
inflammatory hypernociception
In the next part of this study, we tested the hypothesis
that caspase-1 mediates inflammatory hypernociception
by its action on IL-1b or IL-18 processing. Although
carrageenin-induced mechanical hypernociception was
not reduced in IL-18 null mice compared with WT
mice (Figure 4A), the treatment of mice with IL-1ra
(3-90 mg/kg, i.v. 15 min before carrageenin injection)
reduced carrageenin-induced hypernociception in a
dose-dependent manner (Figure 4B).On the other hand,
IL-1ra treatment did not alter carrageenin-induced neu-
trophil migration toward mice paws (Figure 4C). The
implication of IL-1b processing in the role of caspase-1
in inflammatory hypernociception was supported by the
fact that while the increase in the expression of mRNA
for pro-IL-1b induced in the mice paw by carrageenin
was similar in WT and casp1-/- (Figure 4D), the expres-
sion of mature IL-1b (~19 kDa) was reduced in casp1-/-
(Figure 4E). Densitometric analyses of the bands are
present in Figure 4F.
Peripheral COX-2 induction and PGE2 production depends
on caspase-1
Because it was previously demonstrated that the induc-
tion of COX-2 expression and the production of the
direct-acting hypernociceptive mediator, PGE2, during
inflammatory hypernociception is mediated by IL-1b [6];
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we evaluated the contribution of caspase-1 in these
events. Western blot analyses revealed that the increase
in the COX-2 expression induced by carrageenin in WT
mice is reduced in casp1-/- mice (Figure 5A). Densito-
metric analyses of the bands are present in Figure 5B.
The reduction in COX-2 expression was also associated
with a decrease in the production of PGE2 in casp1-/-
mice compared with WT mice (Figure 5C).
Discussion
Caspase-1, originally described as interleukin converting
enzyme, is an intracellular enzyme that plays a role in
the maturation of two important mediators of inflamma-
tion, IL-1b and IL-18 [14-16]. Recently, it was suggested
that caspase-1 also metabolises another inflammatory
mediator, IL-33; however, contrary to IL-1b and IL-18,
it seems that caspase-1 action upon IL-33 produces an
Figure 1 The involvement of caspase-1 in mechanical inflammatory hypernociception. (A) Mechanical nociceptive threshold of wild type
and casp1-/- mice using the electronic von Frey. (B) Wild type or casp1-/- mice received an intraplantar injection of carrageenin (100 μg/paw).
Mechanical hypernociception was evaluated 3 and 5 h after carrageenin injection. (C) Mice were pretreated with a caspase-1 inhibitor (YVAD-
CMK, 1-9 mg/kg s.c. 30 min before) followed by intraplantar injection of carrageenin (100 μg/paw). Mechanical hypernociception was evaluated
3 h after carrageenin injection. Data are expressed as the mean ± S.E.M. of 5 animals per group. * indicates statistical significance compared to
the saline injected group; # statistical significance compared to wild type or vehicle-treated group. P < 0.05, one-way ANOVA followed by the
Bonferroni’s test.
Figure 2 Role of neutrophils and cytokines in caspase-1 mediation of inflammatory hypernociception. (A-B) Wild type and casp1-/- mice
received an intraplantar injection of carrageenin or saline. After 3 h, plantar tissue samples were removed and the levels of TNF-a and CXCL1/KC
were determined by ELISA. (C) At 3 h after carrageenin injection, the activity of MPO was determined in the mice paw skin of wild type and
casp1-/- mice as an index of neutrophil migration. Data are expressed as the mean ± S.E.M. of 5 animals per group. * indicates statistical
significance compared to the saline-injected group. P < 0.05, one-way ANOVA followed by the Bonferroni’s test.
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inactive form of this cytokine [17]. In the present study,
we demonstrated that caspase-1 plays a crucial role in
the cascade of events involved in the genesis of inflam-
matory hypernociception. Indeed, caspase-1 null mice
present a reduction in carrageenin-induced hypernoci-
ception, and a selective inhibitor of caspase-1 presents
an antinociceptive effect in this mice model. Our pre-
sent results corroborate a previous finding of Elford
et al. (1995) that showed that the treatment of rats with
a selective inhibitor of caspase-1 reduced mechanical
hypernociception in a model of yeast-induced inflamma-
tion [12]. Extending these observations, it was recently
shown that caspase-1 mediates the induction of a com-
plex regional pain syndrome that developed after tibia
fracture in rats [18].
It is well known that the release of cytokines in the
inflammatory site is involved in the induction of inflam-
matory hypernociception. In addition, it seems that
these pro-nociceptive cytokines are released sequentially
[6]. In this cascade, TNFa and chemokines, such as
CXCL1/KC, are released earlier [6]. Investigating
whether caspase-1 might account for the release of
these two cytokines, we detected that the levels of
TNFa and CXCL1/KC in carrageenin-inflamed mice
paws are similar in WT and casp1-/- mice, suggesting
that the caspase-1 pro-nociceptive role is downstream of
TNFa and CXCL1/KC. Our results also refute that the
pro-nociceptive role of caspase-1 in carrageenin inflam-
mation is dependent on its capacity to process IL-18.
This conclusion is based in the fact that IL-18 null mice
present similar hypernociception after carrageenin paw
injection compared with WT mice. Nonetheless, the
involvement of caspase-1 in complex regional pain syn-
drome triggered by tibia fracture seems to be dependent
on IL-18 processing [18]. Moreover, IL-18 also plays a
role in the genesis of hypernociception in a model of
immune inflammation induced by ovalbumin in pre-
viously immunised mice, and in this model caspase-1
might be responsible for IL-18 processing [19]. We also
recently showed that besides cytokines, the recruitment
of neutrophils to inflammatory sites mediates carragee-
nin-induced hypernociception [7]. However, it is also
seems that the caspase-1 pro-nociceptive role is not
related to neutrophils, because neutrophil accumulation
in the mice paws of casp1-/- is similar to WT mice.
TNFa and CXCL-1/KC hypernociceptive roles in car-
rageenin inflammation were demonstrated to be, at least
in part, dependent on the production of IL-1b [6]. This
fact, together with our present observation that casp1-/-
mice present reduced hypernociception induced by
Figure 3 Role of caspase-1 in the mechanical hypernociception induced by pro-nociceptive cytokines and PGE2. (A) Wild type or
casp1-/- mice received an intraplantar injection of TNF-a (100 pg/paw), CXCL1/KC (10 ng/paw or IL-1b (1 ng/paw). Mechanical hypernociception
was evaluated 3 h after cytokines injection. (B) Wild type or casp1-/- mice received and intraplantar injection of PGE2 (100 ng/paw). Mechanical
hypernociception was evaluated 0.5, 1.0, and 1.5 h after PGE2 injection. Data are expressed as the mean ± S.E.M. of 5 animals per group.
* indicates statistical significance compared to the saline-injected group; # indicates statistical significance compared to wild type group.
P < 0.05, one-way ANOVA followed by the Bonferroni’s test.
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TNF-a and CXCL1/KC but not by IL-1b and PGE2, is
strongly suggestive that caspase-1 could be mediating
inflammatory hypernociception through its product,
mature IL-1b. Indeed, we detected that while the mRNA
for pro-IL-1b increased at the same levels in casp1-/-
and WT mice after carrageenin injection, there was a
reduction in the mature form of IL-1b in casp-1-/-
mice. This suggestion was supported by the observation
that IL-1ra treatment reduced carrageenin-induced
hypernociception. Corroborating the idea that IL-1b
processing is the mechanism by which caspase-1 med-
iates inflammatory hypernociception, it was observed
that IL-1ra treatment did not alter the neutrophil migra-
tion induced by carrageenin similarly observed in
casp1-/- mice. It is somehow striking because IL-1b
hypernociceptive effect is dependent on neutrophil
migration [7]. At this moment, we have the hypothesis
that that in carrageenin-induced inflammation neutro-
phils are recruited mainly by TNFa and CXCR2 ligands
(CXCL1/KC in mice or CINC-1 in rats) and they are
activated in the site of inflammation by IL-1b that in
turn induced the expression of COX-2 and the produc-
tion of PGE2.
Although casp1-/- mice present a reduction in the
expression of the mature form of IL-1b during carragee-
nin-induced paw inflammation, these mice still present
the residual production of active IL-1b, suggesting that
alternative mechanisms might trigger the induction of
mature IL-1b in this model. For instance, there is evi-
dence that pro-IL-1b can be cleaved by other proteases
Figure 4 IL-1b maturation, but not maturation of IL-18, is involved in caspase-1 mediation of inflammatory hypernociception. (A) Wild
type or IL-18-/- mice received an intraplantar injection of carrageenin (100 μg/paw). Mechanical hypernociception was evaluated 3 h after
carrageenin injection. Mice were pretreated with IL-1ra (3-90 mg/kg, i.v. 15 min before carrageenin injection) followed by intraplantar injection of
carrageenin (100 μg/paw). Mechanical hypernociception was evaluated 3 h after carrageenin injection. (C) After the determination of
hypernociception, mice paw skins were removed and the activity of MPO was determined. (D) Wild type and casp1-/- mice received an
intraplantar injection of carrageenin or saline. After 1.5 h, plantar tissue samples were removed and the level of pro-IL-1b mRNA was determined
by real-time PCR. (D) Wild type and casp1-/- mice received an intraplantar injection of carrageenin or saline. After 3 h, plantar tissue samples
were removed and the level of mature IL-1b (~19 kDa) was determined by western blot. The b-actin level was used as a control. Data are
presented as representative blots. Densitometry of the pixel intensity of IL-1b bands relative to b-actin is present. Data are expressed as the
mean ± S.E.M. of 5 animals per group. * indicates statistical significance compared to the saline-injected group; # indicates statistical significance
compared to the vehicle-treated group or wild type mice group. P < 0.05, one-way ANOVA followed by the Bonferroni’s test.
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in addition to caspase-1, including elastase, proteinase 3
matrix metalloprotease 9 (MMP9), which are produced
by neutrophils recruited to sites of tissue damage
[20-23]. In this context, we have recently shown that
MMP9 mediates hypernociception that developed dur-
ing antigen-induced arthritis, a model in which IL-1b
also plays a role [24].
Besides peripheral participation in the development of
inflammatory hypernociception, we could not disregard
the fact that caspase-1 might be involved by playing a
central role in the response. In fact, activation of cas-
pase-1 in the spinal cord has been associated with an
increase of central IL-1b production that promotes
COX-2 dependent inflammatory hypernociception [13].
In the periphery, the pro-nociceptive effect of IL-1b was
also mediated by cyclooxygenase-derived PGE2 because
its effect was inhibited by treatment with indomethacin
[6,25]. Therefore, the observation that COX-2 expres-
sion and PGE2 production are reduced in casp1-/- mice
challenged with carrageenin corroborates the impor-
tance of IL-1b in these processes. Contrary to these
results, it was shown that although spinal glial-derived
IL-1b is fundamental for the development of neuro-
pathic pain after peripheral nerve injury, caspase-1 is
not involved in this process [23]. It was clearly demon-
strated that, in this model, MMP-9 and MMP-2 are the
enzymes responsible for IL-1b maturation playing a cen-
tral role in neuropathic pain induction [23].
One question that emerges from these results is how
caspase-1 is activated during carrageenin-induced paw
inflammation. Regarding the mechanisms that trigger
caspase-1 activation in the inflammatory process, there
is now a large body of recent evidence showing that
they are dependent on the assembly of cytosolic
multiprotein complexes known as inflammasomes
[26,27]. Inflammasomes are formed by self-oligomerising
scaffold proteins belonging to the NOD-like receptor
family. There are, at least, four different inflammasomes:
NALP1/NLRP1, NALP3/NLRP3, IPAF/NLRC4 and the
HIN-200 family member, AIM2 [26]. These molecules
self-oligomerise after stimuli recognition and form high-
molecular weight complexes that trigger caspase-1 auto-
activation. Therefore, an interesting question is: which
inflammasome is activated during carrageenin inflamma-
tion? In our knowledge, there is no study that addresses
this issue. However, one can predict the involvement of
the NALP3 inflammasome. This suggestion is based on
the following indirect evidence: a) NALP3-containing
inflammasomes that activate caspase-1 generally depend
on stimulation of P2X7 [28]; b) P2X7 mediates carragee-
nin-induced inflammatory hypernociception [29,30]; and
c) P2X7 mediation of inflammatory hypernociception
depends on stimulation of IL-1b because the antinoci-
ceptive effect of a selective P2X7 receptor antagonist is
lost in IL-1 knockout mice [30]. Collectively, these data
suggest that NALP3 is the inflammasome that triggers
caspase-1 activation in the mediation of carrageenin-
induced inflammatory hypernociception, yet other
inflammasomes could be also involved. For instance, the
NALP1 inflammasome is required for caspase-1 activa-
tion and mediates the complex regional pain syndrome
that developed after tibia fracture in rats [18]. Therefore,
additional studies using, for example, NALP3 null mice
are required to solve this question.
In summary, the present study presents evidence that
caspase-1 is involved in the genesis of inflammatory
Figure 5 Role of caspase-1 in the induction of COX-2 and prostaglandin production during carrageenin-induced inflammation. (A) Wild
type and casp1-/- mice received an intraplantar injection of carrageenin (100 μ/paw) or saline. After 3 h, plantar tissue samples were removed
and the expression of COX-2 was determined by western blot. The b-actin level was used as a control. Data are presented as representative
blots. (B) Densitometry of the pixel intensity of COX-2 bands relative to b-actin is present. (C) Wild type and casp1-/- mice received an
intraplantar injection of carrageenin (100 μ/paw) or saline. After 3 h, plantar tissue samples were removed and the level of PGE2 was determined
by RIA. Data are expressed as the mean ± S.E.M. of 5 animals per group. * indicates statistical significance compared to the saline-injected group;
# indicates statistical significance compared to the wild type group. P < 0.05, one-way ANOVA followed by the Bonferroni’s test.
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hypernociception. The participation of caspase-1 in this
inflammatory symptom was not associated with the pro-
duction of pro-inflammatory cytokines (TNFa, CXCL1/
KC or IL-18) and recruitment of neutrophils, but was
associated with the maturation of IL-1b in the inflam-
matory site. Caspase-1 seems to also be involved in the
induction of COX-2 and consequently in the production
of the directly-acting hypernociceptive mediator, PGE2.
Together, these results added new information about
the physiopathology of inflammatory pain. In conclu-
sion, it is plausible to suggest that caspase-1 constitutes
a real target to control inflammatory pain.
Methods
Animals
The experiments were performed on male C57BL/6
mice (wild type, WT, 20-25 g) and caspase-1 deficient
mice (casp1-/-). Breeding pairs of mice with targeted
disruption of the caspase-1 gene were back-crossed with
C57BL/6 for 8 generations. BALB/C mice were used as
a control when the experiment was conducted in IL-18
null mice (IL-18-/-). They were housed in the animal
care facility of the School of Medicine of Ribeirao Preto
and taken to the testing room at least one hour before
the experiments. Food and water were available ad libi-
tum. All behavioural tests were performed between 9:00
AM and 5:00 PM, and the animals were used only once.
Animal care and handling procedures were in accor-
dance with the guidelines of the International Associa-
tion for the Study of Pain (IASP) on the use of animals
in pain research. All efforts were made to minimise the
number of animals used and their discomfort.
Drugs
The drugs used in this study were: prostaglandin E2
(PGE2) (from Sigma, St. Louis, MO), YVAD-CMK (Cal-
biochem, San Diego, CA, USA), TNFa, IL-1b and IL-1
receptor antagonist (IL-1ra) (NIBSC, South Mimms,
Hertfordshire, U.K.), CXCL1/KC (PeproTech, Rocky
Hill, NJ), and carrageenin (FMC, Philadelphia). A stock
solution of PGE2 (1 μg/μL) was prepared in 10% etha-
nol, and dilutions were made in 0.9% NaCl (saline); the
final concentration of ethanol was 1%. Other drugs were
diluted in sterile saline.
Mechanical nociceptive paw test
Mechanical hypernociception was tested in mice as pre-
viously reported [31]. In a quiet room, mice were placed
in acrylic cages (12 × 10 × 17 cm) with wire grid floors
15-30 min before the start of testing. The test consisted
of evoking a hindpaw flexion reflex with a handheld
force transducer (electronic aesthesiometer, IITC Life
Science, Woodland Hills, CA) adapted with a 0.5 mm2
polypropylene tip. The investigator was trained to apply
the tip perpendicularly to the central area of the plantar
hindpaw with a gradual increase in pressure. The gra-
dual increase in pressure was manually performed in
blinded experiments. The upper limit pressure was 15 g.
The end-point was characterised by the removal of the
paw followed by clear flinching movements. After paw
withdrawal, the intensity of the pressure was automati-
cally recorded, and the final value for the response was
obtained by averaging three measurements. The animals
were tested before and after treatments. The results are
expressed by the delta (Δ) withdrawal threshold (in g)
calculated by subtracting the zero-time mean measure-
ments from the mean measurements at the indicated
times after drug or solvent (control) injections. The
withdrawal threshold was 8.9 ± 0.2 g (mean ± S.E.M.;
n = 30) before injection of the solvent or hypernocicep-
tive agents.
Cytokine measurements
At indicated times after the injection of inflammatory
stimuli, the animals were terminally anesthetised, and
the skin tissues of the plantar region were removed
from the injected and control paws (saline and naïve).
The samples were triturated and homogenized in 500 μl
of the appropriate buffer (phosphate-buffered saline
containing 0.05% Tween 20, 0.1 mM phenylmethylsul-
phonyl fluoride, 0.1 mM benzethonium chloride, 10
mM EDTA and 20 kallikrein international units of apro-
tinin A) followed by a centrifugation of 10 min at
2000 g. The supernatants were used to determine the
levels of TNF-a and CXCL1/KC as described previously
[32] by enzyme-linked immunosorbent assays (ELISA).
Briefly, microtiter plates were coated overnight at 4°C
with an immunoaffinity-purified polyclonal sheep anti-
body against TNFa (2 μg/mL) or CXCL1/KC (1 μg/mL).
After blocking the plates, recombinant murine TNFa or
CXCL1/KC standards at various dilutions and the sam-
ples were added in duplicate and incubated overnight at
4°C. Rabbit biotinylated immunoaffinity-purified anti-
body anti- anti-TNFa (1:500) or CXCL1/KC (0.2 μg/
mL) were added, followed by incubation at room tem-
perature for 1 h. Finally, 50 μL of avidin-HRP (1:5000
dilution; DAKO A/S, Denmark) was added to each well,
and after 30 min the plates were washed and the colour
reagent OPD (200 μg/well; Sigma) was added. After
15 min, the reaction was stopped with 1 M H2SO4 and
the optical density (O.D.) reading at 490 nm was taken.
The results are expressed as picograms (pg) of each
cytokine per paw.
Neutrophil migration to the plantar tissue
Neutrophil migration to the hind paw plantar tissues of
mice was evaluated using a myeloperoxidase (MPO)
kinetic-colorimetric assay as previously described
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[33,34]. Samples of subcutaneous plantar tissue were
collected in 50 mM K2HPO4 buffer (pH 6.0) containing
0.5% hexadecyltrimethylammonium bromide (HTAB)
and kept at -80°C until use. Samples were homogenised
using a Polytron (PT3100), centrifuged at 16,100 g for
4 min, and the resulting supernatant was assayed for
MPO activity spectrophotometrically at 450 nm (Spectra
max), with three readings in 1 min. The MPO activity
of samples was compared to a standard curve of neutro-
phils. Briefly, 10 μL of sample was mixed with 200 μL of
50 mM phosphate buffer, pH 6.0, containing 0.167 mg/
mL O-dianisidine dihydrochloride and 0.0005% hydro-
gen peroxide. The results are presented as MPO activity
(number of neutrophils per mg of tissue).
RNA extraction and Real-Time PCR
At 1.5 h after intraplantar (i.pl.) injection of carrageenin
or saline, mice were terminally anesthetised, and skin
tissues were removed from the plantar region of paws.
The samples were homogenised in 1 mL of TRIzol
(Invitrogen, Carlsbad, CA) and total RNA was extracted
following the manufacturer’s instructions. The purity of
total RNA was measured with a spectrophotometer and
the wavelength absorption ratio (260/280 nm) was
between 1.8 and 2.0 for all preparations. Reverse tran-
scription of total RNA to cDNA was carried out with a
reverse transcription reaction (Superscript II, Gibco Life
Technologies, Grand Island, NY, USA). Real-time PCR
was performed using primers specific for the mouse
gene pro-IL-1b and for the mouse housekeeping gene
hypoxanthine guanine phosphoribosyl transferase
(Hprt). Reactions were conducted on the ABI Prism
7500 Sequence Detection System using the SYBR-green
fluorescence system (Applied Biosystems, Warrington,
UK). The data were analysed with the 2−ΔΔCt method as
described previously [35] and they are expressed relative
to samples collected in the saline group of animals. Pri-
mer pairs for mouse Hprt and pro-IL-1b were as
follows:
pro-IL-1b fwd: 5′-GCTGCTTCCAAACCTTTGAC-3′
pro-IL-1b rev: 5′-AGCTTCTCCACAGCCACAAT-3′
Hprt fwd: 5′-GCCCCAAAATGGTTAAGGTT- 3′
Hprt rev: 5′-CAAGGGCATATCCAACAACA- 3′
Western blot analysis
At 3 h after i.pl. injection of carrageenin or saline, mice
were terminally anesthetised, and skin tissues were
removed from the plantar region of paws. The samples
were homogenised and the expression of cyclooxygenase
(COX-2; ~72 kDa) or the mature form of IL-1b (~19
kDa) were evaluated using western blot analyses. Briefly,
samples were homogenised in a lysis buffer containing a
mixture of proteinase inhibitors (Tris-HCl 50 mM, pH
7.4; NP-40 1%; Na-deoxycholate 0.25%; NaCl 150 mM;
EDTA 1 mM; PMSF 1 mM; Aprotinin, leupeptin and
pepstatin 1 μg/mL each). Proteins were separated by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE-
12%) and transblotted onto nitrocellulose membranes
(Amersham Pharmacia Biotech, Little Chalfont, UK).
The membranes were blocked with 7% dry milk (over-
night) and incubated overnight at 4°C with a rabbit
polyclonal antibody against COX-2 (1:400; Cayman,
Ann Arbor, Michigan, USA) or IL-1b (1:200, Santa
Cruz, CA, USA). After these procedures, the membranes
were washed and then incubated for 1 h at room tem-
perature with an HRP-conjugated secondary antibody
(1:20000; Jackson ImmunoResearch, PA, USA). The
blots were visualised in ECL solution (Amersham Phar-
macia Biotech) for 2 min and exposed onto sheets of
Hyperfilm (Amersham Pharmacia Biotech) for 2-20 min.
A b-actin (1:2000; AbCam, Cambridge, MA, USA) anti-
body was used for loading controls. A total of ten wes-
tern blot runs were performed and transferred to eight
nitrocellulose membranes with proteins of the saline
group and carrageenin injection group in WT and casp-
1-/- mice. Films were scanned into Image Quant 5.2 for
analysis. A computer-based imaging system (Gel-Pro
Analyzer) was used to measure the intensity of the opti-
cal density of the ~70 kDa and ~19 kDa bands that
represent the molecular weight of COX-2 and the
mature form of IL-1b proteins.
Measurement of PGE2 in paw skin
The plantar tissues were collected 3 h after intraplantar
injection of carrageenin (100 μg/paw) or saline as
described above. This time point is the peak of carragee-
nin-induced PGE2 production in the mice paw (data not
shown). The paws were injected with indomethacin (50
μg/paw) 10 min before tissue retrieval to block PGE2
production during tissue processing. The PGE2 was
extracted from plantar tissue and determined by radio-
immunoassay [7]. Briefly, the plantar tissue samples
were homogenized in a mixture of 3.0 ml of extraction
solvent (isopropanol/ethyl acetate/0.1 N HCl, 3:3:1) and
3.0 ml of distilled water. Also, the solution contained 20
μg/ml of indomethacin. Homogenates were centrifuged
at 1,500 g for 10 min at 4°C. The organic phase was
aspirated and evaporated to dryness in a centrifugal eva-
porator. The pellet was reconstituted in 500 μl of 0.1 M
phosphate buffer (pH 7.4) containing 0.8% sodium azide
and 0.1% gelatin. Concentration of PGE2 in these sam-
ples was then measured by RIA by using a commercially
available kit. The results are expressed as picograms of
PGE2 per paw.
Paw oedema test
The volume of the mice paw was measured with a
plesthismometer (Ugo Basil, Italy) before (Vo) the
Cunha et al. Molecular Pain 2010, 6:63
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intraplantar stimulus with carrageenan and 3 h after
(VT), as described previously [34]. The amount of paw
swelling was determined for each mouse and the differ-
ence between VT and Vo was taken as the oedema
value (oedema mm3/paw).
Statistical analysis
All results are presented as means ± S.E.M. The experi-
ments were repeated at least twice. The “n” in the
legends refers to the number of mice used in the experi-
mental group of each experiment. The differences
between the experimental groups were compared by
ANOVA (one-way) and individual comparisons were
subsequently made with Tukey’s post hoc test. The level
of significance was set at P < 0.05.
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